RecruitingPhase 2NCT06260072

Magnesium and Riboflavin Treatment for Post-Concussion Headache

Sponsor

University of Virginia

Enrollment

108 participants

Start Date

Feb 10, 2020

Study Type

INTERVENTIONAL

Conditions

Concussion, Intermediate

Summary

This clinical trial will try to determine if the supplements magnesium and riboflavin will reduce the pain and duration of headaches in persons diagnosed with a concussion. The participant will be randomized to either active magnesium and riboflavin capsules or placebo (inert) capsules. The capsules will be taken once a day for 14 days. The participant will also complete a short diary form for the 14 days and will have 3 follow up visits either by telephone or in person.

Eligibility

Min Age: 18 YearsMax Age: 40 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called magnesium and riboflavin supplement for people with concussion, intermediate. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 40 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGmagnesium and riboflavin supplement

Five capsules considered one dose of the intervention (one 400 mg magnesium capsule and four 100 mg riboflavin capsules)

Locations(1)

University of Virginia Student Health and Wellness Center

Charlottesville, Virginia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06260072

Related Trials

Facilitating Access to Specialty Treatment

NCT057414111 location